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Abstract 
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor 
with an extremely poor prognosis in spite of multimodal treatment approaches. The 
estimated median survival in cases with GBM is about 12–16 months. Those patients who 
survive ≥3 years after the initial diagnosis are defined as long-term survivors. In this 
study, we retrospectively analyze 50 consecutive cases of Bulgarian patients with newly 
diagnosed GBM surgically treated at our institution for a period of 1 year. Four of them 
survived for more than 36 months after the initial intervention. The histological re-
examination revealed features typical of primary GBM in 3 of these cases, which are 
described in detail in the present paper. A brief review of the relevant literature is also 
given. 
 
Introduction 
Glioblastoma multiforme (GBM) is the most common and malignant primary brain 
tumor with an extremely poor prognosis in spite of aggressive treatment, consisting of 
surgery followed by chemoradiation and adjuvant chemotherapy [1, 2]. The estimated 
median survival in cases with GBM is about 12–16 months [3, 4]. Those patients who 
survive ≥3 years after the initial diagnosis are defined as long-term survivors [5, 7].  
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Aims 
The aims of our study were: (1) to determine the rate of long-term survivors in an 
unselected group of Bulgarian patients operated on for the first time with histologically 
confirmed GBM, (2) to verify the histological diagnosis in each of them, and (3) to 
determine factors associated with favorable clinical outcome in those with established 
primary GBM. 
Material and Methods 
We retrospectively analyze 50 consecutive cases of Bulgarian patients with newly diagnosed GBM 
surgically treated at our institution between January and December 2006. Four of them survived for 
more than 3 years after the initial intervention. Histological re-examination of the tumor samples 
revealed features typical of primary GBM in 3 of these cases. The fourth patient was excluded from the 
study because of the presence of large gemistocytic areas which suggested the diagnosis of a secondary 
GBM. 
Case Reports 
Case 1 
A 57-year-old female with known Crohn’s disease was admitted at the clinic with a 10 weeks’ history 
of progressive headache. Physical examination showed signs and symptoms of increased intracranial 
pressure (ICP) without any focal neurological deficit. The Karnofsky Performance Scale (KPS) score at 
the time of admission was estimated at 90. The familial history of the patient was unremarkable. 
Magnetic resonance imaging (MRI) revealed right-sided temporobasal lesion with compression of the 
adjacent brain structures (fig. 1a). Subtotal excision of the tumor was performed without development 
of additional neurological deficit. Histological examination revealed typical features of GBM without 
any areas of differentiation (fig. 2). The patient underwent subsequent conventional external-beam 
radiotherapy (RT) with a total dose of 60 Gy followed by 2 courses of adjuvant temozolomide (TMZ). A 
progressive headache occurred 9 months after the initial surgery. MRI revealed a residual tumor at the 
site of intervention (fig. 1b). The patient was reoperated on with a gross total removal of the lesion. 
Histological examination showed the same findings as previously. The patient improved after the 
procedure with regard to increased ICP. Eighteen courses of TMZ were consequently administered. 
Forty-three months after the diagnosis, the patient is feeling well without neuroimaging evidence of 
recurrent disease (fig. 1c, d). 
Case 2 
A 52-year-old male was referred to our department with a 4 weeks’ history of progressive headache. 
Except signs and symptoms of increased ICP, the neurological status of the patient was rated normal. 
The KPS score was calculated at 90. The familial history revealed that the father suffered from colorectal 
carcinoma. MRI showed an intraparenchymal lesion situated in the right temporoparietal region with 
compression of the lateral ventricle and dislocation of the midline structures to the left (fig. 3a). 
Subtotal tumor removal was performed in emergency because of the development of extensive 
intratumoral hemorrhage soon after the admission. The neurological condition of the patient gradually 
improved after the procedure. Histological examination revealed ‘classic’ GBM (fig. 4). After the 
surgery, the patient underwent chemoradiation in standard regimens followed by 4 cycles of adjuvant 
TMZ. He was symptom free for 4 months, but then the headache reappeared. MRI revealed local 
progression of the residual tumor (fig. 3b). Subtotal excision of the lesion was performed with the same 
histological result. The patient’s headache improved after the procedure. Twenty-five courses of TMZ  
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were consequently administered. At the end of the study (January 31, 2010), the patient is feeling well 
with the only complaint of slight left arm paresis (follow-up = 43 months). 
Case 3 
A 56-year-old female presented with a 4 weeks’ history of progressive headache. Physical 
examination revealed signs and symptoms of increased ICP, slight left-sided hemiparesis, and left 
homonymous hemianopsia. KPS score was estimated at 80. The patient’s familial history indicated that 
her mother had died of a brain tumor of unknown histology. MRI showed a hetero-intense lesion 
situated in the right parieto-occipital region with compression of the occipital horn of the lateral 
ventricle (fig. 5a). Gross total tumor removal was performed without subsequent neurological 
deterioration (fig. 5b). Histology confirmed the diagnosis of a primary GBM (fig. 6). The patient 
underwent RT with concomitant TMZ 2 months after surgery, followed by 10 cycles of adjuvant TMZ. 
No tumor regrowth was noted on further MRI controls (follow-up = 39 months; fig. 5c, d). At the end of 
the study, the patient’s only complaint is persistent left homonymous hemianopsia. 
Discussion 
The 3-year survival rate in cases with GBM varies between different authors. In 1999, 
Scott et al. [6] reported on 689 unselected patients with histologically confirmed GBM. 
Fifteen of them (2.2%) were classified as long-term survivors. In 2004, Ohgaki et al. [8] 
published a population-based study of 715 newly diagnosed GBM cases. The authors 
claimed that survival rate at 3 years was 1.2%, despite the fact that not all of the cases were 
followed until death. However, more recent studies demonstrate increased long-term 
survival probabilities. For example, in 2008, Filippini et al. [9] reported on a long-term 
survival rate of 7% in 676 consecutive patients with histologically confirmed primary 
GBM. One year later, Sonoda et al. [10] and Glas et al. [11] estimated long-term survival 
rates of 14.6 and 18.5%, respectively. According to our data, the long-term survival 
probability in Bulgarian patients with newly diagnosed GBM is 8%. 
A number of studies have been addressed to define factors capable of predicting which 
GBM patient will become a long-term survivor. We consider that all these factors can be 
classified into the following 3 groups: 
Patient-Dependent Factors 
Most authors agree that young age at presentation is a predictor of long-term survival 
in patients with GBM [6, 12–17]. For example, in 1993, Chandler et al. [12] estimated a 
mean age of 39.2 years in a group of 22 long-term survivors. This finding was confirmed 
by many other subsequent studies: Archibald et al. [13] (1994) – 37.7 years, Morita et al. 
[14] (1996) – 39.2 years, Scott et al. [6] (1999) – 43.5 years, Burton et al. [15] (2002) – 39 
years, McLendon and Halperin [16] (2003) – 40.2 years, and Steinbach et al. [17] (2006) – 
42.0 years. Interestingly, in 2007, Krex et al. [7] indicated a median age of 51 years which 
was significantly higher from that reported before. However, it seems that patient age >60 
years is more likely to be associated with poor clinical outcome [18, 19]. The mean age of 
our long-term survivors is 55 years (range, 52–57 years), which does not correspond with 
the literature.  
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The true impact of gender on the survival is not clearly estimated. Some authors claim 
that female gender is a predictor of long-term survival in patients with GBM. For 
example, in 2004, Shinojima et al. [20] described 6 cases with a survival of more than 5 
years. All 6 were women, with a mean age of 44.2 years.
 However, other authors reported 
equal or even inverse sex distribution [5, 16]. In our study, females outnumbered males by 
a ratio of 2:1. 
It is proven that a KPS score ≥80 before surgery correlates with improved GBM 
survival. In 1999, Scott et al. [6] demonstrated that long-term survivors had a higher 
mean KPS score compared with controls. On the other hand, in 2009, Chaichana et al. 
[19] found that a KPS score ≤80 is associated with unfavorable clinical outcome. These 
findings are supported by many other reports [9, 20, 21]. All 3 patients included in our 
study had KPS scores of ≥80 at the time of admission, which is comparable with the 
literature. 
Although the clinical presentation of GBM may not differ significantly between long-
term and short-term survivors, it has been demonstrated that absence of major 
neurological deficit prior to surgery is associated with better prognosis [19]. Furthermore, 
a longer duration of signs and symptoms is more likely to be found in long-term survivors 
– 52 versus 7.2 weeks [21]. In our study, the leading patient complaints were associated 
with increased ICP. The mean symptom duration was 6 weeks (range, 4–10 weeks), which 
is not typical for long-term survivors. 
Tumor-Dependent Factors 
There is an agreement that patients with secondary GBM survived significantly longer 
than those with primary GBM [8, 22]. According to Ohgaki et al. [8], this can be 
explained by the younger age of the cases with
 secondary GBMs rather than a reflection of 
different
 biological behavior. All 3 cases described here fulfilled the accepted criteria for 
primary GBM: a short clinical history (less than 3 months) and typical histopathological 
findings of GBM at the first biopsy. 
In 1993, Simpson et al. [23] failed to find any influence of tumor size prior to surgery 
on GBM survival. On the contrary, in 2004, Jeremic et al. [24] demonstrated that patients 
who had tumors of 4 cm in size or less did better when compared to those with larger 
lesions. However, both authors agree that frontal tumor location is associated with better 
survival, probably because of the possibility for more extensive surgical removal. The 
tumor was right-sided in all long-term survivors described here. The frontal lobe was not 
involved in any of the cases. 
The classical histological predictors of long-term survival include: presence of giant 
cells, focal oligodendroglial differentiation, and absence of small anaplastic elements [7, 
16, 20, 25–28]. In 2004, Shinojima et al. [20] were able to detect giant cells exclusively in 
long-term survivors. In 2005, Deb et al. [27] identified areas of oligodendroglial 
differentiation in 2 of 6 tumors investigated. According to McLendon and Halperin [16], 
intermediate fibrillary elements are more common and small anaplastic elements are less 
common in long-term survivors. The histological re-evaluation revealed typical features 
of primary GBM in 3 of our long-term survival cases. One patient was excluded from the  
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study because of the presence of large gemistocytic areas which suggested the diagnosis of 
a secondary GBM. 
It is obvious that routine histopathological grading has limited capacity to predict 
GBM survival. Currently, efforts are focused on detecting molecular markers of long-term 
survival [1, 29]. It has been demonstrated that TP53 overexpression is more likely and 
MDM2 overexpression is less likely to be found in long-term survivors [30]. In 2002, 
Burton et al. [15] demonstrated 19q chromosomal loss exclusively in long-term survival 
cases. Interestingly, EGFR overexpression was not detected in any of the long-term 
survivors described by Deb et al. [25]. The authors found TP53 positivity in 4 of the 5 
tumors investigated. In 2005, Korshunov et al. [31] described 46 copy number aberrations 
strongly associated with GBM outcome. Using array-based comparative genomic 
hybridization analysis, the authors found 26 copy number aberrations associated with 
short-term and 20 – with long-term survival. In 2007, Krex et al. [7] demonstrated 
MGMT hypermethylation in 28 of 36 tumors (77.7%) investigated. They also found TP53 
mutations in 9 of 31 cases (29.0%) and EGFR overexpression in 10 of 38 cases (26.3%). 
Only 2 of 32 cases (6.3%) carried a combined 1p and 19q deletion. Recently, Carro et al. 
[32] identified 2 genes – C/EBP-β and STAT3, the inactivation of which was strongly 
associated with long-term survival. Unfortunately, no patient in the present study had 
been investigated in search for molecular predictors. 
Treatment-Dependent Factors 
The actual therapeutic approach in the cases with GBM consists of surgery followed by 
chemoradiation and adjuvant chemotherapy [33, 34]. Most authors agree that a more 
aggressive treatment is associated with prolonged survival [1, 2, 4, 6, 9, 18, 22, 24]. 
Interestingly, in 2001, Sabel et al. [28] reported on a 69-year-old patient who survived for 
more than 17 years after the diagnosis of giant cell GBM. The patient had not undergone 
any postoperative RT or adjuvant chemotherapy and died without clinical evidence of 
GBM recurrence. 
It seems that gross total tumor removal is not essential for long-term survival. For 
example, in 1993, Chandler et al. [5] found such a radical excision in only 2 of 22 long-
term survivors investigated. This finding was confirmed later by McLendon and Halperin 
[15]. In our study, gross total tumor excision was achieved in one patient and subtotal in 
the other two, who were consequently reoperated. 
RT with concomitant and adjuvant TMZ has become the standard of care for patients 
with newly diagnosed GBM [34]. In a study of 39 long-term survivors, Hottinger et al. 
[35] found that all patients had received RT. Interestingly, concomitant TMZ was 
administered only in 18% of them. It seems that combination between RT and 
nitrosourea may increase long-term survival rate. For example, in 2009, Sonoda et al. [10] 
published a study of 123 consecutive GBM patients initially treated by maximum tumor 
resection followed by RT and intravenous injection of nimustine hydrochloride. Using 
this strategy, the authors reported on a long-term survival rate of 14.6%. Subsequent 
chemoradiation in standard regimens was performed in two of the patients included in 
our study; the other patient underwent RT alone. All patients received at least 10 courses 
of adjuvant TMZ until the end of the study period (range, 10–29 cycles).  
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Conclusion 
This is the first clinical study to determine the rate of long-term survivors in an 
unselected group of Bulgarian patients with newly diagnosed GBM. Further prospective 
trials with a large number of patients are needed to determine the factors associated with 
favorable clinical outcome in cases with primary GBM. 
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Fig. 1. MRI scans of case 1. Axial contrast-enhanced T1-weighted image before the first intervention 
(a); sagittal contrast-enhanced T1-weighted scan at the second admission (b); axial contrast-enhanced 
T1-weighted controls 4 months later (c), and at the end of the study (d). 
 
 
 
Fig. 2. Histological findings of case 1. The tumor displays marked hypercellularity (a, H&E ×200), 
many mitoses (b, H&E ×400), pseudopalisading necroses and microvascular proliferation (c, H&E 
×200). 
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Fig. 3. MRI images of case 2. Axial contrast-enhanced T1-weighted scan at the first admission (a); axial 
contrast-enhanced T1-weighted image before the second surgery (b); axial contrast-enhanced T1-
weighted scans 6 months later (c), and at the end of the study (d). 
 
 
 
Fig. 4. Histological findings of case 2. The tumor shows hypercellularity, prominent cellular 
polymorphism, and mitoses (a, H&E ×400). Pseudopalisading necroses (b, H&E ×400) and 
microvascular proliferation (c, H&E ×400) are also seen. 
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Fig. 5. MRI and computed tomography scans of case 3. Axial T2-weighted image before the initial 
intervention (a); control computed tomography scan on the second postoperative day (b); axial 
contrast-enhanced T1-weighted images 18 months later (c), and at the end of the study (d). 
 
 
 
Fig. 6. Histological findings of case 3. The tumor displays pseudopalisading necroses (a, H&E ×200), 
hypercellularity with frequent mitotic figures (b, H&E ×400), and microvascular proliferation (c, H&E 
×200). 
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